Trial Profile

A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KIVU 107 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Gastrointestinal cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Sarcoma; Small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Kivu Bioscience

18 Nov 2025 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health;NCT07229313)
13 Nov 2025 Status changed from planning to not yet recruiting.
20 Oct 2025 According to a Kivu Bioscience media release, this trial is expected to begin in this quarter.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com